Brief: Targovax's ONCOS-102 Mesothelioma 12-Month Data Demonstrate Broad Immune Activation Linked To Clinical Benefit

Circio Holding ASA

22/06/2020 06:04

June 22 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX'S ONCOS-102 MESOTHELIOMA 12-MONTH DATA POWERFULLY
DEMONSTRATE BROAD IMMUNE ACTIVATION LINKED TO CLINICAL BENEFIT
    * MECHANISTIC EVIDENCE OF PROFOUND IMMUNE ACTIVATION IN
ONCOS-102-TREATED PATIENTS ASSOCIATED WITH BETTER CLINICAL
OUTCOMES
    * IMMUNE ACTIVATION DATA PROVIDES CLEAR SCIENTIFIC RATIONALE
FOR
ANTI-PD1/L1 CHECKPOINT INHIBITOR COMBINATION IN UPCOMING TRIAL
IN FIRST LINE MESOTHELIOMA OSLO, NORWAY, 22 JUNE 2020
    * 12-MONTH SURVIVAL RATE WAS 64% IN FIRST LINE ONCOS-102
TREATED
PATIENTS, COMPARED TO 50% IN FIRST LINE CONTROL GROUP TREATED
WITH SOC CHEMOTHERAPY ONLY (MEDIAN OVERALL SURVIVAL IS TOO EARLY
TO REPORT)

Source text for Eikon:  ID:nWkr4Rm97l 
Further company coverage:  TRVX.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))